Chemcon Speciality Chemicals Ltd
₹ 199
-1.01%
21 May
- close price
About
Incorporated in 1988, Chemcon Speciality Chemicals Ltd manufactures Pharmaceutical intermediates and Oilfield Chemicals[1]
Key Points
- Market Cap ₹ 730 Cr.
- Current Price ₹ 199
- High / Low ₹ 298 / 160
- Stock P/E 29.9
- Book Value ₹ 137
- Dividend Yield 0.00 %
- ROCE 7.02 %
- ROE 5.00 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -4.57% over past five years.
- Company has a low return on equity of 7.05% over last 3 years.
- Earnings include an other income of Rs.14.3 Cr.
- Dividend payout has been low at 8.86% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
53 | 63 | 97 | 88 | 158 | 303 | 262 | 243 | 257 | 303 | 267 | 207 | |
46 | 56 | 87 | 79 | 112 | 237 | 192 | 162 | 175 | 232 | 240 | 175 | |
Operating Profit | 6 | 8 | 10 | 9 | 46 | 66 | 70 | 81 | 82 | 71 | 27 | 33 |
OPM % | 12% | 12% | 10% | 10% | 29% | 22% | 27% | 33% | 32% | 23% | 10% | 16% |
0 | -1 | 0 | 0 | 0 | 2 | 4 | 5 | 9 | 13 | 13 | 14 | |
Interest | 2 | 2 | 3 | 2 | 3 | 4 | 5 | 4 | 1 | 1 | 4 | 3 |
Depreciation | 1 | 2 | 2 | 2 | 2 | 3 | 5 | 6 | 6 | 8 | 10 | 11 |
Profit before tax | 3 | 3 | 5 | 5 | 41 | 61 | 65 | 76 | 84 | 74 | 26 | 33 |
Tax % | 60% | 3% | 35% | 37% | 35% | 30% | 25% | 26% | 25% | 26% | 27% | 26% |
1 | 3 | 3 | 3 | 26 | 43 | 49 | 56 | 63 | 55 | 19 | 24 | |
EPS in Rs | 1.46 | 3.35 | 4.09 | 3.78 | 33.21 | 13.54 | 15.37 | 15.40 | 17.13 | 15.04 | 5.24 | 6.67 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 27% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | -5% |
3 Years: | -7% |
TTM: | -22% |
Compounded Profit Growth | |
---|---|
10 Years: | 23% |
5 Years: | -13% |
3 Years: | -27% |
TTM: | 28% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -12% |
1 Year: | -20% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 11% |
3 Years: | 7% |
Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 8 | 32 | 32 | 37 | 37 | 37 | 37 | 37 |
Reserves | 11 | 13 | 16 | 19 | 46 | 65 | 115 | 317 | 381 | 421 | 440 | 464 |
14 | 12 | 13 | 20 | 17 | 33 | 46 | 6 | 36 | 64 | 43 | 25 | |
12 | 10 | 9 | 15 | 27 | 43 | 34 | 44 | 45 | 32 | 26 | 29 | |
Total Liabilities | 45 | 44 | 46 | 63 | 97 | 173 | 226 | 404 | 498 | 553 | 545 | 554 |
20 | 20 | 19 | 24 | 30 | 40 | 49 | 67 | 82 | 141 | 146 | 149 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 9 | 34 | 14 | 42 | 40 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 |
25 | 24 | 27 | 38 | 67 | 133 | 173 | 328 | 382 | 398 | 356 | 355 | |
Total Assets | 45 | 44 | 46 | 63 | 97 | 173 | 226 | 404 | 498 | 553 | 545 | 554 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
7 | 5 | 10 | 14 | 11 | 12 | 65 | 74 | 13 | 12 | 41 | ||
-5 | -2 | -9 | -7 | -24 | -16 | -152 | -92 | -16 | -25 | -19 | ||
-3 | -3 | -2 | -6 | 12 | 4 | 111 | 30 | 12 | -25 | -22 | ||
Net Cash Flow | -1 | -0 | -1 | 1 | -0 | 0 | 23 | 11 | 9 | -37 | 0 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 40 | 52 | 51 | 93 | 68 | 77 | 124 | 142 | 146 | 81 | 112 | 91 |
Inventory Days | 146 | 74 | 45 | 58 | 99 | 91 | 118 | 175 | 102 | 164 | 119 | 261 |
Days Payable | 97 | 79 | 39 | 81 | 82 | 57 | 63 | 67 | 70 | 44 | 23 | 49 |
Cash Conversion Cycle | 89 | 47 | 57 | 70 | 86 | 111 | 179 | 250 | 177 | 201 | 208 | 303 |
Working Capital Days | 85 | 64 | 59 | 79 | 93 | 95 | 175 | 189 | 155 | 184 | 220 | 272 |
ROCE % | 17% | 17% | 22% | 16% | 74% | 65% | 43% | 29% | 21% | 15% | 6% | 7% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Investor Presentation 2d
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 May - Newspaper Advertisement - Audited Financial Results for the quarter and financial year ended March 31, 2025
-
Announcement under Regulation 30 (LODR)-Resignation of Director
14 May - Independent Director Lalit Devidutt Chaudhary resigned on 14 May 2025 due to time constraints.
- Audited Financial Results For The Quarter And Financial Year Ended March 31, 2025. 14 May
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, 14Th May 2025
14 May - Audited FY25 financial results approved; unmodified audit opinion; auditor appointments for FY26 confirmed.
Annual reports
Concalls
-
May 2025TranscriptNotesPPT
-
Feb 2025TranscriptNotesPPT
-
Oct 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Dec 2020Transcript PPT
Business Overview:[1]
CSCL is an ISO 9001:2015 and ISO 14001:2015 certified manufacturer of silanes, pharma intermediates, agro intermediates, and oil field chemicals. It is the largest manufacturer of specialized chemicals like HMDS and CMIC, predominantly used in the pharmaceutical industry.